Savant Capital LLC Sells 307 Shares of Danaher Co. (NYSE:DHR)

Savant Capital LLC trimmed its holdings in shares of Danaher Co. (NYSE:DHR) by 0.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 39,521 shares of the conglomerate’s stock after selling 307 shares during the period. Savant Capital LLC’s holdings in Danaher were worth $9,072,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. FMR LLC lifted its holdings in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after purchasing an additional 428,897 shares in the last quarter. Montrusco Bolton Investments Inc. lifted its holdings in shares of Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after purchasing an additional 397,671 shares in the last quarter. Finally, Union Bancaire Privee UBP SA bought a new position in shares of Danaher in the 4th quarter worth $74,551,000. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 11.10% of the stock is currently owned by insiders.

Danaher Trading Down 1.6 %

Shares of DHR opened at $203.42 on Tuesday. The business has a 50-day moving average of $232.72 and a 200 day moving average of $251.61. Danaher Co. has a fifty-two week low of $203.00 and a fifty-two week high of $281.70. The firm has a market cap of $146.92 billion, a P/E ratio of 38.53, a price-to-earnings-growth ratio of 2.68 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the company posted $2.09 earnings per share. As a group, research analysts forecast that Danaher Co. will post 7.67 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.53%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is currently 20.45%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on DHR. Barclays cut their target price on Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. TD Cowen increased their price target on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Jefferies Financial Group lowered their price target on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Robert W. Baird lowered their price target on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Finally, Scotiabank initiated coverage on Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target for the company. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.